Rationale Nicotine is a major active ingredient in tobacco and plays a major role in tobacco addiction. In rodents, repeated nicotine administration produces behavioral responses related to its addictive properties, such as reinforcing effects and physical dependence. Objectives The aim of the present study was to evaluate the possible role of GABA B receptor in responses induced by repeated nicotine administration in Swiss Webster mice. Results Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) administration induced rewarding properties in the conditioning place preference test. The GABA B receptor agonist, baclofen (3 mg/kg, i.p.) abolished the rewarding properties induced by nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.). In addition, naloxone-precipitated nicotine withdrawal induced somatic manifestations, anxiety-like effects in the elevated plus maze test and dysphoric manifestations in the conditioned place aversion paradigm. Baclofen (2 and 3 mg/kg, i.p.) prevented the somatic manifestations and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal but not the dysphoric manifestations. Conclusions These results showed that nicotine rewarding properties and negative aspects of nicotine withdrawal, such as anxiety-like effects and somatic manifestations, can be modulated by the GABA B receptor activity. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation.
Introduction
Nicotine is a major active ingredient in tobacco smoke and plays a major role in tobacco addiction (Stolerman and Jarvis 1995) . Nicotine produces its pharmacological responses by acting on nicotinic acetylcholine receptors (nAChRs) that are mainly located at a presynaptic level (Dani 2001) .
The activation of these receptors by nicotine increases the release of several neurotransmitters, including dopamine, noradrenaline, serotonin, acetylcholine, glutamate and GABA (in Picciotto and Corrigall 2002) . The varied properties of the nAChRs can result in different patterns of neurotransmitter release following acute and chronic nicotine administration, accounting for the complex behavioral effects of nicotine (in .
People smoke to experience the psychoactive effects of nicotine, like mild euphoria, increased energy, heightened arousal, reduced stress and anxiety, and improve cognitive function, such as concentration, reaction time, and task performance (Pomerleau 1986; Gilbert et al. 1989) . In rodents, Laboratori de Neurofarmacologia, Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra, C/Dr. Aiguader, 88, 08003 Barcelona, Spain acute nicotine administration modifies a large number of physiological processes such as locomotion, nociception, anxiety, learning and memory, as well as repeated nicotine administration produces several behavioral responses directly related to its addictive properties, including rewarding effects and physical dependence (Decker et al. 1995) .
Preclinical studies support the idea that a number of GABAergic drugs, particularly the GABA B receptor agonist baclofen, decreases the abstinence signs from different drugs, such as ethanol (File et al. 1991) , barbitone (Sandoval and Palermo-Neto 1985) , and morphine (Diaz et al. 2001) . Baclofen also reduces craving for several addictive drugs, including heroin, alcohol, and nicotine (Colombo et al. 2000; Corrigall et al. 2000; Spano et al. 2007 ). In addition, baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens (NAc) of rat (Fadda et al. 2003) . Interestingly, baclofen prevents nicotine rewarding properties in rats Le Foll et al. 2008) and the activation of GABA B receptor in the ventral tegmental area (VTA) attenuates the rewarding properties of psychostimulants and nicotine (Cousins et al. 2002) . Our laboratories have extensively explored the behavioral and neurochemical effects of nicotine addiction. Indeed, we have previously observed an interaction between the GABAergic and nicotinic cholinergic systems, given that baclofen prevented the somatic manifestation and neurochemical changes induced by mecamylamine-precipitated nicotine withdrawal in mice (Varani et al. 2011) . On the other hand, the GABA B antagonist, 2-OH-saclofen, blocked the anxiolytic-and anxiogenic-like effects induced by nicotine . Finally, we recently showed that acute behavioral responses to nicotine (antinociception, hypolocomotion, and anxiety-like effects) and nicotine withdrawal syndrome are modified in GABA B1 knockout mice .
Taken together, these results suggest that several behavioral responses of nicotine related to its addictive properties can be modulated through the activity of GABA B receptors. The aim of the present study was to clarify the behavioral effects of baclofen on two important responses related to nicotine dependence: nicotine rewarding properties and the emotional and somatic manifestation of nicotine withdrawal. Several behavioral responses induced by repeated nicotine administration were evaluated in Swiss Webster mice pretreated with baclofen. Nicotine reinforcing properties were investigated using the place preference paradigm. In addition, the somatic manifestations and the anxiety-like effects induced by naloxone-precipitated nicotine withdrawal were evaluated. Finally, the conditioned place aversion paradigm was used to evaluate the aversive motivational state associated with nicotine withdrawal.
Materials and methods

Animals
Male Swiss Webster mice obtained from Bioterio Central (Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Argentina) weighing 22-24 g were housed five per cage, acclimated to the laboratory conditions according to local regulation (SENASA 2002) (12-h light:12-h dark cycle, 21±0.5°C room temperature, 65±10 % humidity) and manipulated for 3 days prior to the experiment for handling habituation. Food and water were available ad libitum. Behavioral tests and animal care were conducted in accordance with the standard ethical guidelines (European Community Guidelines on the Care and Use of Laboratory Animals 86/ 609/EEC and 2001-486/EEC) and approved by the local ethical committee. All experiments were performed with the investigators being blind to the treatment conditions. Drugs (−)-Nicotine hydrogen tartrate salt ([−]-1-methyl-2-[3-pyridyl]pyrrolidine) and naloxone hydrochloride (SigmaAldrich, USA) were dissolved in physiological saline (0.9 % NaCl) and administered by the subcutaneous route. Nicotine doses used were calculated as nicotine hydrogen tartrate salt. (±) Baclofen (Novartis, Basel, Switzerland) was dissolved in physiological saline (0.9 % NaCl) and administered by intraperitoneal route. Nicotine, naloxone, and baclofen were administered in a volume of 10 mL/kg. Nicotine doses are reported as nicotine hydrogen tartrate salt (1 mg/kg of nicotine hydrogen tartrate salt equals to 0.35087 mg/kg nicotine free base).
Place preference paradigm
In a different set of animals, the rewarding effects of nicotine hydrogen tartrate salt (0.5 mg/kg, sc) were evaluated by using the conditioned place preference paradigm, as previously described (Maldonado et al. 1997; Matthes et al. 1996) . The apparatus consisted of two main square conditioning compartments separated by a triangular central division. During the preconditioning phase, each mouse was placed in the middle of the central division and had free access to both compartments of the conditioning apparatus for 18 min, with the time spent in each compartment recorded by computerized monitored software (Vision Robot®, Buenos Aires, Argentina). Treatments were counterbalanced between compartments in order to use an unbiased procedure. No initial place preference or aversion for the different compartments was observed in any of the experiments. In the conditioning phase, saline and nicotine hydrogen tartrate salt conditioning sessions were conducted daily over the next 4 days. Each day, animals were injected with saline and placed into corresponding chamber for 20 min. Four hours later, animals were injected with nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) and placed in the opposite chamber for 20 min. Control animals received saline every session in both chambers. The test phase was conducted exactly as for the preconditioning phase, i.e., free access to both compartments during 18 min, and the time spent in each compartment was recorded. The time in the central area was proportionally shared and added to the time value of each compartment as previously described (Maldonado et al. 1997; Valverde et al. 1996) . A score value was calculated for each mouse as the difference between the time spent in the drug-paired compartment during the testing and preconditioning phases. Baclofen (1, 2, and 3 mg/kg, i.p.) or vehicle was administered 45 min before nicotine injection during the conditioning phase to evaluate their effect on the acquisition of the place preference.
Nicotine dependence and withdrawal
Induction of nicotine dependence
Mice were implanted subcutaneously with Alzet osmotic minipumps (Model, 2001 ) (Alzet®, Cupertino, CA), under brief diethyl ether anesthesia. The minipumps contained saline or nicotine hydrogen tartrate salt solutions and delivered a constant subcutaneous flow at a rate of 1 μL/h. The concentration of nicotine hydrogen tartrate salt was adjusted to compensate for differences in the body weight of the subjects. Thus, average-weight mouse received a dose of approximately 25 mg/kg/day nicotine hydrogen tartrate salt over 6 days. Two different set of mice were used to evaluate the somatic signs and the anxiety-like effects associated with naloxoneprecipitated nicotine withdrawal.
Naloxone-precipitated nicotine withdrawal: somatic signs
Nicotine withdrawal syndrome was precipitated 6 days after minipump implantation by injection of the μ-opioid receptor antagonist naloxone (3 mg/kg, s.c.). The somatic signs of withdrawal were visually recorded by one observer during a period of 15 min before and 30 min after naloxone injection, as previously reported (Balerio et al. 2004 ). The number of wet dog shakes, front paw tremors, writhes, and scratches was counted. Body tremor, ptosis, teeth chattering, genital licks, and piloerection were scored 1 for appearance or 0 for nonappearance within each 5 min time. The locomotor activity over 5-min periods was rated 0, 1, or 2 (0 for inactivity, 1 for low activity, and 2 for normal activity). A global withdrawal score was calculated for each animal by giving each individual sign a relative weight, as previously reported (Castañé et al. 2002) . Baclofen (1, 2, and 3 mg/kg, i.p.) or vehicle was administered 45 min before naloxone injection.
Naloxone-precipitated nicotine withdrawal: anxiety-like effects
Other set of nicotine-dependent mice received a naloxone (3 mg/kg, s.c.) injection in order to precipitate the nicotine withdrawal and were immediately placed in the elevated plus maze test. The elevated plus maze (Pellow et al. 1985; File et al. 1992 ) consisted of a black plastic apparatus with fours arms (16×5 cm) set in a cross from a neutral central square (5×5 cm). Two opposite arms were delimited by vertical walls (closed arms), while the other two opposite arms had unprotected edges (open arms). The maze was elevated 30 cm above the ground and illuminated from the top (100 lx). At the beginning of the 15-min observation session, each mouse was placed in the central neutral area, facing one of the open arms. The total number of visits to the closed and open arms and the cumulative time spent in the open and closed arms were then observed on a monitor through a video camera system (Vision Robot). An arm visit was recorded when the mouse moved both forepaws and the head into the arm, as we previously described (Balerio et al. 2005) . Baclofen (1, 2, and 3 mg/kg, i.p.) or vehicle was administered 45 min before naloxone injection.
Conditioned place aversion induced by naloxone-precipitated nicotine withdrawal
In a different set of animals, the place conditioning paradigm was used to evaluate the effect of baclofen (2 mg/kg) on the dysphoric manifestations associated with nicotine withdrawal. The apparatus consisted of two main square conditioning compartments separated by a triangular neutral area (Maldonado et al. 1997 ). The time spent by the mouse in each compartment was recorded by computerized monitoring software (Videotrack®, View Point, France). In order to induce nicotine dependence in animals, mice were implanted subcutaneously with osmotic minipumps (Alzet®, Model 2002) under brief diethyl ether anesthesia. The minipumps contained saline or nicotine hydrogen tartrate salt and delivered a constant flow in a rate of 0.5 μL/h. The concentration of nicotine will be adjusted to compensate for differences in the body weight of the mice, and average-weight mouse received a dose of approximately 10 mg/kg/day nicotine hydrogen tartrate salt over 14 days. In the present study, naloxone (0.12 mg/kg, s.c.) was used to precipitate the aversive manifestations of nicotine withdrawal.
Five days after minipumps implantation, the preconditioning phase was performed. Each animal was placed in the neutral area, allowing to freely explore the conditioning compartments, and the time spent in each compartment was recorded during 18 min. Animals did not show any initial preference or aversion for the two compartments. Mice were distributed in the different treatment groups counterbalancing the drug-paired compartments. In the conditioning phase, animals received baclofen (2 mg/kg, i.p.) or vehicle 45 min before the withdrawal induction by the administration of naloxone (0.12 mg/kg, s.c.) or saline (control group) on days 7, 9, 11, and 13 after minipump implantation. Then, they were immediately confined in the withdrawal-paired compartment by using guillotine doors matching walls for 30 min. On days 8, 10, 12, and 14 after minipump implantation, all mice received vehicle 45 min before saline injection, and were then immediately confined in the saline-paired compartment for 30 min. The post-conditioning phase was conducted on day 18 after minipump implantation, i.e., 4 days after the end of the nicotine infusions. This phase was performed as the preconditioning phase, i.e., animals were placed in the neutral area and had free access to the conditioning compartments during 18 min. The time spent in the central area was proportionally distributed and added to the time spent in each compartment, as previously reported (Maldonado et al. 1997) . A score was calculated for each mouse as the difference between the post-conditioning and preconditioning time spent in the drug-paired compartment.
Statistical analysis
The score values of nicotine place conditioning experiments, the somatic signs, and the anxiety-like behavior associated with nicotine withdrawal were analyzed using two-way ANOVA with chronic treatment (saline or nicotine) and acute treatment (vehicle or baclofen) as between-subjects factors of variation, followed by corresponding post hoc test when appropriate (Fisher's test). For the place aversion conditioning experiments, score values were compared using one-way ANOVA for each chronic treatment (saline and nicotine) followed by Fisher's post hoc test.
Results
Baclofen blocked nicotine rewarding properties
We investigated the effect of baclofen (1, 2, and 3 mg/kg, i.p.) on the acquisition of nicotine hydrogen tartrate salt (0.5 mg/kg, sc) rewarding properties in the place conditioning paradigm (Fig. 1) . Baclofen pretreatment (3 mg/kg) blocked the rewarding properties induced by nicotine (Fig. 4) . Two-way ANOVA revealed a significant effect of nicotine treatment [F (1,102) = 92.855, p<0.001], baclofen pretreatment [F (3,102) =9.188, p < 0.001] and interaction between these two factors [F (3,102) =11.621, p<0.001]. Subsequent post hoc (Fisher) analysis revealed a significant effect of nicotine treatment in the vehicle-and baclofen-pretreated (1 and 2 mg/kg) mice (p<0.001 and p<0.001, respectively), but not in those mice which were pretreated with 3 mg/kg of baclofen. Post hoc also showed a significant blockade in the rewarding properties induced by nicotine in the baclofen (p<0.001) (3 mg/kg, i.p.) but not in the vehicle-pretreated animals (Fig. 1) .
Baclofen prevented the somatic expression of nicotine withdrawal
The following somatic signs were significantly revealed in the different experimental groups: paw tremor, body tremor, teeth chattering, genital licks, wet dog shakes, scratches, ptosis, piloerection, and locomotor activity (see Table 1 for twoway ANOVA and Fisher's post hoc test). Comparisons between saline-and nicotine-treated groups receiving acute vehicle pretreatment (Fisher's post hoc test) showed that nicotine withdrawal produced a significant incidence of paw tremor (p < 0.001), body tremor (p< 0.001), teeth chattering (p<0.001), and wet dog shakes (p<0.05) (Fig. 2) . In addition, baclofen (3 mg/kg) pretreatment significantly decreased paw tremor (p<0.001), body tremor (p<0.001), teeth chattering (p<0.001), and wet dog shakes (p<0.05) in nicotine withdrawal mice in comparison to mice pretreated with vehicle (Fig. 2) .
The analysis of the global withdrawal score (see Table 1 for two-way ANOVA and Fisher's post hoc test) confirmed that baclofen (3 mg/kg) significantly prevented the severity of nicotine withdrawal. The severity of nicotine withdrawal was significant in vehicle (p<0.001) but not in baclofenpretreated mice, in comparison to nondependent mice. In addition, the global withdrawal score was significantly reduced in nicotine-dependent mice pretreated with baclofen Fig. 1 Baclofen (3 mg/kg, i.p.) blocked the rewarding properties induced by nicotine. The effect of baclofen (BAC; 1, 2, and 3 mg/kg, i.p.) on the rewarding properties induced by nicotine hydrogen tartrate salt (NIC; 0.5 mg/kg, s.c.) in the place conditioning paradigm was investigated in mice. Results are represented as the difference between post-conditioning and preconditioning time spent in the drug-paired compartment. BAC or vehicle (VEH,0.9 % NaCl) was administered 45 min before NIC or saline (SAL, 0.9 % NaCl) injection during the conditioning phase. Data are expressed as mean±SEM (n=12-18 mice for each group). Statistical analysis was performed using two-way ANOVA with chronic treatment (SAL or NIC) and acute treatment (VEH or BAC) as between-subjects factors of variation, followed by Fisher's post hoc test. ★★★ p<0.001 when compared to VEH group. ☆☆☆ p<0.001 comparisons between similar groups receiving SAL or NIC (3 mg/kg) in comparison to those pretreated with vehicle (p<0.001) (Fig. 2) .
Baclofen prevented the anxiety-like effects associated with nicotine withdrawal
We investigated the effect of baclofen (1, 2, and 3 mg/kg) on anxiety-like behavior induced by naloxone-precipitated nicotine withdrawal in the elevated plus maze test (Fig. 3) . Baclofen pretreatment (3 mg/kg) blocked the anxiety-like behavior induced by naloxone-precipitated nicotine withdrawal (Fig. 3) (Fig. 3a) . In addition, the decreased percentage of entries into the open arms induced by nicotine withdrawal was significantly prevented in baclofen-pretreated (2 and 3 mg/kg) (p<0.001) mice, but not in those mice which were pretreated with baclofen 1 mg/kg (Fig. 3a) . On the other hand, two-way ANOVA revealed a significant effect of nicotine treatment [F (1,66) (Fig. 3b) . In addition, the decreased percentage of time spent in the open arms induced by nicotine withdrawal was significantly prevented in baclofen-pretreated (2 mg/kg, p<0.05 and 3 mg/kg, p<0.001) mice, but not in those mice which were pretreated with baclofen 1 mg/kg (Fig. 3b) .
Baclofen did not modify the dysphoric manifestations of nicotine withdrawal
The effect of baclofen (2 mg/kg, i.p.) pretreatment on the dysphoric manifestations of naloxone-precipitated nicotine withdrawal was analyzed (Fig. 4) . Time spent in the withdrawal-paired compartment during pretest was similar in the different experimental groups, which ensures the use of an unbiased procedure (one-way ANOVA, [F (5,74) =0.1243, p= 0.987], data not shown). No abnormal behavior was observed during the conditioning phase after the administration of naloxone (0.12 mg/kg). Fisher's post hoc test revealed a significant decrease in the score of vehicle-and baclofen-pretreated nicotine-dependent animals conditioned to naloxoneprecipitated withdrawal as compared to vehicle-pretreated Two-way ANOVA with chronic treatment (saline or nicotine) and acute treatment (saline or baclofen) as between-subjects factors, followed by corresponding post hoc test when appropriate (Fisher's test).
To simplify the table, the comparison between Sal-Sal and Sal-Bac is not shown, since it was not significant in any case. See "Materials and methods" for details nicotine-dependent animals conditioned with saline (p<0.05). No significant changes were observed when comparing vehicle-or baclofen-pretreated mice, revealing that conditioned place aversion induced by naloxone in nicotinetreated mice was not modified by baclofen pretreatment (Fig. 4) .
Discussion
The effects of baclofen administration have been evaluated on the chronic effects of nicotine. Our results demonstrate that acute baclofen administration prevented rewarding properties induced by nicotine. Baclofen also prevented the somatic signs and anxiety-like effects, but not the dysphoric manifestations associated with naloxone-precipitated nicotine withdrawal. Acute rewarding effects of drugs of abuse are responsible for the initiation of the addictive process (in Koob and Le Moal 2001) . Nicotine acute rewarding properties were investigated in mice by using the place conditioning paradigm.
Nicotine hydrogen tartrate salt (0.5 mg/kg, s.c.) induced a significant place preference, as expected (Berrendero et al. 2002 (Berrendero et al. , 2005 Castañé et al. 2002 Castañé et al. , 2006 Trigo et al. 2009 ) and baclofen did not produce any intrinsic response in this paradigm, in agreement with previous studies (Heinrichs et al. 2010) . In the present study, baclofen (3 mg/mg, i.p.) blocked the nicotine conditioned place preference, suggesting that GABA B receptor activity would be involved in the rewarding effects of nicotine. In agreement, baclofen prevents the nicotine rewarding properties in the place conditioning paradigm in rats (Le Foll et al. 2008) . Moreover, baclofen has been reported to reduce nicotine rewarding effects in the rat selfadministration paradigm (Corrigall et al. 2000; Fattore et al. 2002; Paterson et al. 2004) . In addition, a recent report showed that baclofen blocked the reinstatement of extinguished nicotine place preference in mice (Fattore et al. 2009 ). Therefore, GABA B receptor activation would modulate nicotine selfadministration, the reinstatement of extinguished nicotine place preference, as well as the acquisition of nicotine place preference in mice. The effect of baclofen here observed could be related to its capacity to activate GABA B receptors located postsynaptically in dopaminergic neurons of the VTA Fig. 2 Baclofen (3 mg/kg, i.p.) prevented the somatic expression of naloxone-precipitated nicotine withdrawal. Counted (wet dog shakes and paw tremor) and checked (body tremor, genital licks, ptosis, teeth chattering, and piloerection) somatic signs of withdrawal were observed during 30 min immediately after naloxone (3 mg/kg, s.c.) administration. Baclofen (BAC; 1, 2, and 3 mg/kg, i.p.) or vehicle (VEH, 0.9 % NaCl) was administered 45 min before withdrawal. A global withdrawal score was calculated for each animal as described in the methods. Data are expressed as mean±SEM (n=10-14 mice for each group). Statistical analysis was performed using two-way ANOVA with chronic treatment (saline, SAL, 0.9 % NaCl or nicotine hydrogen tartrate salt, NIC, 25 mg/kg/day) and acute treatment (VEH or BAC) as between-subjects factors of variation, followed by Fisher's post hoc test. ★ p<0.05, ★★★ p<0.001 when compared to VEH group. ☆ p<0.05, ☆☆☆ p<0.001 comparisons between similar groups receiving chronic SAL or NIC (Laviolette and van der Kooy 2004) , causing a decrease of dopamine release in the NAc (Fadda et al. 2003) , leading to the blockade of nicotine rewarding effects (Cousins et al. 2002) .
Importantly, acute baclofen administration prevented the somatic expression of naloxone-precipitated nicotine withdrawal, as revealed by the significant decrease of relevant somatic signs, such as paw tremors, body tremor, teeth chattering, and wet dog shakes. Nicotine dependence was induced by using minipumps delivering a constant rate of nicotine hydrogen tartrate salt solution over a 6-day period and the μ-opioid receptor antagonist naloxone (3 mg/kg, s.c.) precipitated a withdrawal syndrome, as previously reported (Balerio et al. 2004; Biała et al. 2005 ). Naloxone did not modify somatic signs by itself, in agreement with previous studies (Diaz et al. 2001; Luo et al. 2012; Mori et al. 2013 ). In addition, naloxone administration has been widely used to precipitate withdrawal in nicotine-dependent rodents (Adams and Cicero 1998; Carboni et al. 2000; Malin et al. 1993) , and also induces somatic signs of nicotine withdrawal in chronic smokers (Krishnan-Sarin et al. 1999) , presumably by a possible blockade of nAChRs (Tome et al. 2001) . Conversely, human clinical trials showed that another opioid antagonist (naltrexone) decreases nicotine withdrawal signs in chronic smokers (Epperson et al. 2010; Toll et al. 2010; King et al. 2012) , which support the possible effect of naloxone on nAChRs (Tome et al. 2001) . Together, these effects reveal the role of the endogenous opioid system in nicotine abstinence (Houdi et al. 1998; Isola et al. 2002; Berrendero et al. 2002 Berrendero et al. , 2005 . The present study revealed that baclofen pretreatment prevented the somatic manifestations of naloxoneprecipitated nicotine withdrawal, suggesting that GABA B receptors would be involved in the control of nicotine withdrawal signs. Similarly, we have previously shown that baclofen prevented the somatic signs of nicotine withdrawal precipitated in mice by the selective nicotinic receptor antagonist mecamylamine (Varani et al. 2011) , and this nicotine withdrawal syndrome was abolished in GABA B1 knockout mice . The effects of baclofen in preventing naloxone-precipitated nicotine withdrawal signs were not due to changes in locomotion since no significant differences between saline-saline and saline-baclofen groups were revealed (see Table 1 for locomotor activity sign), in agreement with previous studies (Diaz et al. 2001; Varani et al. 2011; Villas Boas et al. 2012 ). In addition, baclofen did not induce motor incoordination or sedation, as confirmed by the rota-rod test (Balerio and Rubio 2002) . Therefore, our results suggest the involvement of GABA B receptors on naloxoneprecipitated nicotine withdrawal syndrome, which could imply the existence of a possible interaction between the opioid, GABAergic, and nicotine neurotransmitter systems (in administration. Baclofen (BAC; 1, 2, and 3 mg/kg, i.p.) or vehicle (VEH, 0.9 % NaCl) was administered 45 min before withdrawal. Data are expressed as mean±SEM (n=8-10 mice for each group). Statistical analysis was performed using two-way ANOVA with chronic treatment (saline, SAL, 0.9 % NaCl or nicotine hydrogen tartrate salt, NIC, 25 mg/kg/day) and acute treatment (VEH or BAC) as between-subjects factors of variation, followed by Fisher's post hoc test. ★★ p<0.01, ★★★ p<0.001 when compared to VEH group. ☆☆ p<0.01, ☆☆☆ p<0.001 comparisons between similar groups receiving chronic SAL or NIC Fig. 4 Baclofen (BAC, 2 mg/kg, i.p.) did not modify the dysphoric manifestations of naloxone-precipitated nicotine (NIC). Naloxone (NLX, 0.12 mg/kg, s.c.) induced nicotine withdrawal place aversion score and was calculated as the difference between the time (seconds) spent in the withdrawal associated compartment during the post-conditioning and the preconditioning phase (see "Materials and methods" for details). Data are expressed as mean±SEM (n=10-14 mice for each group). ★ p<0.05 compared to vehicle-saline (VEH-SAL) group (Fisher's post hoc test) Berrendero et al. 2010; Markou 2001 and Markou 2008) . The prevention of nicotine withdrawal by baclofen as evidenced here could be related to its ability to modulate opioid cells directly connected with dopamine in the striatum (Ma et al. 2012; Miura et al. 2007 ), a brain area involved in nicotine withdrawal expression (Natividad et al. 2010; Rada et al. 2001; Varani et al. 2011) . However, further studies would be required to support this mechanistic explanation.
Several studies in animals Irvine et al. 2001 ) and humans (Parrott and Garnham 1998) have revealed that nicotine withdrawal results in an increased anxiety-like effect, which has been proposed as an affective aspect of nicotine withdrawal. Our results showed that naloxoneprecipitated nicotine withdrawal increased the anxiety-like effects in the elevated plus maze. Similarly, it has been reported that mecamylamine-precipitated (Jackson et al. 2008; Rehni et al. 2012) or spontaneous nicotine withdrawal induce a reduction in exploration of the open arms of the elevated plus maze in mice Jackson et al. 2009; Manhães et al. 2008) . Our results revealed that naloxone alone did not change the elevated plus maze responses when compared to control mice, in accordance to previous reports (Hodgson et al. 2008) . Interestingly, baclofen pretreatment prevented nicotine abstinence-induced anxiety-like effects on the elevated plus maze test, without any intrinsic effect of baclofen on anxiety levels (Dalvi and Rodgers 1996; . Therefore, our study revealed that the anxiety-like effects induced by nicotine withdrawal could be pharmacologically minimized by the activation of GABA B receptors. The effects of baclofen in preventing the anxiety-like responses associated with naloxone-precipitated nicotine withdrawal were not due to changes in locomotion since no significant differences were revealed on the locomotor responses after the different treatments (see Table 1 for locomotor activity sign).
Finally, the effects of baclofen pretreatment were evaluated on the aversive manifestations associated with nicotine withdrawal. The dose of baclofen (2 mg/kg) used in these set of experiments was selected taking into account the results obtained in the experiments of somatic manifestations and the anxiety-like effects associated to naloxone-precipitated nicotine withdrawal. The administration of naloxone precipitated dysphoric manifestations of nicotine withdrawal in nicotinedependent mice, as previously described for mice (Balerio et al. 2004 ) and rats (Ise et al. 2000; Watkins et al. 2000) , indicating that the opioid system is particularly important in the negative emotional states associated with nicotine withdrawal (in Kenny and Markou 2001) . In our experimental conditions, no somatic manifestations of nicotine withdrawal were observed during the conditioning phase in mice receiving this low dose of naloxone (0.12 mg/kg), in agreement with previous studies (Balerio et al. 2004 ). These aversive manifestations of nicotine withdrawal were not modified by the pretreatment with baclofen (2 mg/kg), which had no intrinsic effect as previously reported (Chester and Cunningham 1999) . Therefore, the aversive states produced during naloxoneprecipitated nicotine withdrawal cannot be modulated by the activation of GABA B receptors, at least in our experimental conditions.
In conclusion, we provide herein pharmacological evidence of the specific involvement of GABA B receptors in the regulation of rewarding properties induced by nicotine. Interestingly, the present results also indicate that baclofen administration prevents the expression of somatic signs and the anxiety-like effects associated with naloxone-precipitated nicotine withdrawal in mice, suggesting an interaction between the opioid, GABAergic, and cholinergic systems. The elucidation of this interaction provides a further step towards a better understanding of the complex nicotine behavioral responses in mice. All together, these data underline the interest of GABA B receptor as a potential target for the development of novel therapeutics approaches for nicotine addiction Franklin et al. 2009 ). In addition, based on the available preclinical and clinical studies, we suggested that baclofen could be a promising compound for the treatment of nicotine addiction. This study now reveals a novel possible application of baclofen to develop new therapeutic strategies to achieve smoking cessation.
